FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1405-1406 May 23, 1996 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by del Zoppo, G. J. Related Article by The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group PubMed Citation

To the Editor: In "Tissue Plasminogen Activator [t-PA] for Acute Ischemic Stroke" (Dec. 14 issue),¹ it is reported that treatment with t-PA increases a patient's chance of recovering from an ischemic stroke without any, or only minimal, disability or neurologic deficit. Despite this optimistic conclusion, several methodologic issues and the demonstrated risks of treatment with t-PA suggest a more cautious interpretation. Although the study was randomized, there were important base-line differences that favored the t-PA–treated patients. Overall, more patients in the t-PA–treated group than in the placebo group had been receiving aspirin before the event (odds ratio, 1.697; 95 percent . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Robinson, L., Alexandrov, A. V., Grotta, J. C. (2000). Clototripsy? Response. Stroke 31: 2024-2025 [Full Text]